Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 12:59 PM ET

Biotechnology

Company Overview of Q Therapeutics, Inc.

Company Overview

Q Therapeutics, Inc., through its subsidiary, is engaged in developing human cell-based therapies intended to treat degenerative diseases of the brain and spinal cord, the primary components of the central nervous system. It develops Q-Cells that are healthy human glial cells intended for the treatment of amyotrophic lateral sclerosis, multiple sclerosis, transverse myelitis, traumatic spinal cord injury, stroke, Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease. The company was formerly known as Q Holdings, Inc. and changed its name to Q Therapeutics, Inc. in December 2012. Q Therapeutics, Inc. is based in Salt Lake City, Utah.

615 Arapeen Drive

Suite 102

Salt Lake City, UT 84108

United States

5 Employees

Phone:

801-582-5400

Fax:

801-582-5401

Key Executives for Q Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 65
Chief Financial Officer, Principal Accounting Officer and Vice President of Corporate Development
Age: 56
Senior Director of Research & Development
Regulatory Consultant
Compensation as of Fiscal Year 2014.

Q Therapeutics, Inc. Key Developments

Q Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Q Therapeutics, Inc. filed its 10-K on Mar 31, 2015 for the period ending Dec 31, 2014. In this report its auditor, Tanner + Co., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Q Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 10:45 AM

Q Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 10:45 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Q Therapeutics, Inc. Appoints Hunter Jackson as Independent Member

Q Therapeutics, Inc. announced the appointment of Hunter Jackson, Ph.D. as an independent member to the company's Board of Directors. In addition, Dr. Jackson has agreed to serve on the Board's newly formed Governance and Nominating Committee; he will be joined on the Committee by current independent directors, Peter Grebow, Ph.D. and Peter Barton Hutt, Esq. Dr. Jackson brings to Q Therapeutics more than 30 years' experience in the life science industry.

Similar Private Companies By Industry

Company Name Region
Rousselot Peabody Inc United States
RGene Therapeutics, Inc. United States
Amplimmune, Inc. United States
Smart Biosciences, Inc. United States
Truminim, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Q Therapeutics, Inc., please visit www.qthera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.